Krishna Institute of Medical Sciences Limited (KIMS)
🎯 Key Takeaways
- KIMS is in a high-growth, capital-intensive phase marked by aggressive hospital expansion and service line diversification, particularly in oncology, cardiac, and neuro sciences. Despite strong top-line growth, profitability has declined sharply due to margin pressure from strategic investments and regional imbalances, notably in Karnataka.
- Revenue declined 0.6% QoQ to ₹772 in Q3FY25.
- ⚠️ Karnataka cluster continues to deliver negative EBITDA, posing a persistent drag on consolidated profitability despite strong performance in Telangana
📖 The Story
KIMS is in a high-growth, capital-intensive phase marked by aggressive hospital expansion and service line diversification, particularly in oncology, cardiac, and neuro sciences. Despite strong top-line growth, profitability has declined sharply due to margin pressure from strategic investments and regional imbalances, notably in Karnataka. The company is leveraging scale and operational capacity to drive revenue growth, but profitability recovery remains contingent on regional EBITDA improvement and cost discipline.
📰 What's Happening
In Q1 FY27, KIMS reported consolidated revenue of ₹1,196 crores, up 36.1% YoY, driven by expansion in clinical services and new hospital openings, including 995 additional beds in Kondapur and Palakkad. EBITDA reached ₹240 crores at 20.1% margin, but PAT declined 47.2% YoY to ₹37 crores, reflecting margin compression. Management highlighted robust performance in Telangana (52.2% of revenue, 76.8% of EBITDA) and outlined plans to add 1,500 beds by FY28, expand oncology and cardiac services, and deepen digital-first patient acquisition. The company also completed a ₹1,500 crore Qualified Institutional Placement (QIP) in June 2026, with CARE Ratings confirming zero deviation in fund utilization, though commingling of proceeds in subsidiary accounts has raised governance concerns.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 576 | 606 | 652 | 606 | 634 | 688 | 777 | 772 |
| Operating Profit | 168 | 160 | 180 | 150 | 163 | 184 | 223 | 205 |
| OPM % | 28.3% | 25.9% | 27.2% | 24.3% | 25.1% | 26.1% | 28.1% | 24.2% |
| Net Profit | 99 | 87 | 101 | 77 | 71 | 95 | 121 | 93 |
| EPS | ₹11.65 | ₹10.10 | ₹11.50 | ₹8.98 | ₹8.18 | ₹10.82 | ₹2.68 | ₹2.22 |
Revenue growth has accelerated consistently, with Q1 FY27 revenue up 36.1% YoY to ₹1,196 crores, continuing a multi-quarter trend of double-digit growth from ₹576 crores in Q4 FY23 to ₹1,196 crores in Q1 FY27. However, EBITDA margin has stabilized near 20% despite revenue expansion, while PAT margins have deteriorated significantly, falling from ₹11.65 EPS in Q4 FY23 to ₹1.04 EPS in Q1 FY27. This divergence underscores rising operational costs and investment intensity, particularly in underperforming regions like Karnataka, which posted negative EBITDA. The company’s profitability decline is not due to operational inefficiency but rather deliberate scaling in high-potential but capital-heavy service lines.
🔮 Management Outlook & What's Next
Management expects robust performance in FY27, targeting growth in new hospitals and clinical services, with a specific focus on expanding oncology, cardiac, and neuro sciences. They aim to add 1,500 beds by FY28 and maintain EBITDA margins above 20%, supported by digital lead generation and GIPSA empanelment. However, no formal forward guidance on revenue or PAT was provided in the latest filings. Management emphasized that profitability recovery will be gradual, contingent on regional EBITDA improvement — particularly in Karnataka — and scaling of high-margin specialties.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Healthcare Services
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | 1.16 L Cr | 64.5 | 20.5% | 21.9% | 0.64 |
| Max Healthcare Institute Limited | 1.02 L Cr | 101.2 | — | — | — |
| Fortis Healthcare Limited | 72,752 | 94.6 | — | — | — |
| Aster DM Healthcare Limited | 39,048 | 7.1 | — | — | — |
| Narayana Hrudayalaya Ltd. | 37,625 | 47.7 | — | — | — |
| Global Health Limited | 33,405 | 65.8 | — | — | — |
| Krishna Institute of Medical Sciences Limited | 30,477 | 80.3 | — | — | — |
| Dr. Lal Path Labs Ltd. | 26,871 | 63.6 | — | — | — |
| Syngene International Limited | 18,295 | 36.3 | — | — | — |
| Dr. Agarwal's Health Care Limited | 14,266 | 88.8 | 14.9% | 6.8% | 0.13 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Karnataka cluster continues to deliver negative EBITDA, posing a persistent drag on consolidated profitability despite strong performance in Telangana and other regions. 2. Margin pressure persists due to aggressive investments in clinical infrastructure and digital patient acquisition, with EBITDA margin holding flat at 20.1% despite revenue growth. 3. Governance concerns emerged over the commingling of QIP proceeds in subsidiary accounts, raising questions about fund tracking and auditability, even though CARE Ratings confirmed zero deviation. 4. High valuation (P/E of 80.3) leaves limited room for earnings misses, making near-term profitability recovery a key market expectation.
📋 Recent Filings
-
🔴 Financial Results 3 August 2026KIMS reported consolidated revenue of **₹1,196 crores** for Q1 FY27, up 36.1% YoY and 10.3% QoQ, with EBITDA at **₹240 crores** (20.1% margin). PAT de...
-
🟡 deviation variation 3 August 2026KIMS confirmed no deviation in fund utilization for the quarter ended June 30, 2026, from its Qualified Institutional Placement. The company raised Rs...
-
🔴 Financial Results 3 August 2026KIMS reported Q1 FY27 revenue of **₹11,959 crores**, up **35.3% YoY**, with EBITDA at **₹2,398 crores** (**20.1% margin**) and PAT of **[amount contex...
-
🟡 Board Meeting 3 August 2026KIMS disclosed CARE Ratings' monitoring report for its ₹1,500 crore QIP, confirming full utilization of funds across repayment, subsidiary investments...
-
share transfer 17 July 2026KIMS announced receipt of a SEBI-mandated share transfer agent certificate for the June 2026 quarter, confirming dematerialization of securities and t...
-
Announcement 11 July 2026Krishna Institute of Medical Sciences held an EGM on July 4, 2026 to approve key governance changes including reappointing directors, altering article...
-
🟡 Board Meeting 4 July 2026KIMS issued a corrigendum to its EGM notice dated 15 June 2026, clarifying updated debt figures in the preferential issue disclosure and adding langua...
-
Announcement 23 June 2026Krishna Institute of Medical Sciences Limited announced that it has obtained listing approval from both BSE and NSE for 1,98,67,549 equity shares of R...
-
Announcement 19 June 2026KIMS announced the closure of its qualified institutional placement of 19,867,549 shares at ₹755 each, finalizing allocation and refund procedures aft...
-
🔴 Financial Results 16 June 2026Krishna Institute of Medical Sciences Limited announced the audited standalone and consolidated financial statements for the financial year ended Marc...
🧠 Analyst's Read
KIMS is executing a clear expansion strategy with strong operational momentum, but profitability remains on a lagging trajectory due to regional imbalances and capital intensity. Investors should monitor quarterly EBITDA recovery in Karnataka and the pace of margin improvement in new service lines. The next earnings call will be critical to assess whether PAT decline stabilizes or if cash reserves are being consumed faster than anticipated to fund growth.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-03.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when KIMS files new disclosures
Track KIMS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track KIMS — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research